Phaseline

Companies › OBI Pharma

OBI Pharma: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
adagloxad simolenin (OBI-822)/OBI-821
anti-Globo H glycolipid vaccine with immune adjuvant
–Phase 3Triple Negative Breast CancerDec 2027
OBI-833/OBI-821
Globo H-targeting immunotherapy (cancer vaccine)
GLOBOHPhase 2Non-small Cell Lung Cancer–
OBI-992
Anti-TROP2 antibody-drug conjugate with exatecan payload
TROP2Phase 1Advanced Solid TumorJun 2027
OBI-902
antibody-drug conjugate
–Phase 1Advanced Solid TumorFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05442060OBI-833/OBI-821Phase 2Non-small Cell Lung CancerOncologyDec 2025
NCT06480240OBI-992Phase 1Advanced Solid TumorOncologyJun 2027
NCT03562637adagloxad simolenin (OBI-822)/OBI-821Phase 3Triple Negative Breast CancerOncologyDec 2027
NCT07124117OBI-902Phase 1Advanced Solid TumorOncologyFeb 2029

Targets

TROP2 (1) GLOBOH (1)

Companies with the same targets

GSK Sichuan Baili Pharmaceutical Astellas Beijing Biotech Akeso MacroGenics Mabwell (Shanghai) Bioscience Bio-Thera Solutions LigaChem Biosciences

Companies built like this

Lantheus Medical Imaging Shenzhen TargetRx InxMed (Shanghai) PharmaMar Stemline Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.